TYMS and cancer: By doing so, these compounds, once combined with classical anti-TS drugs in suitably designed anticancer therapeutic schemes, may help avoiding or delaying the onset of anti-hTS drug resistance associated with over-expression of the enzyme, thus maintaining or restoring cancer-cell drug sensitivity.